Department of Hematology and Medical Oncology, Sociedad Española de Oncología Médica (SEOM), Hospital General Universitario Morales Meseguer, Avda. Marqués de los Vélez, s/n, 30008, Murcia, Spain.
Service of Biochemistry, Sociedad Española de Medicina de Laboratorio (SEQCML), Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Clin Transl Oncol. 2021 Jul;23(7):1272-1280. doi: 10.1007/s12094-020-02529-x. Epub 2021 Feb 7.
The measurement of circulating tumour markers (TMs) for the diagnosis or monitoring of breast cancer has sometimes been considered of limited utility. In addition to the overinterpretation of irrelevant changes in marker levels, the characteristics of the patient, the disease or other pathologies that can modify them are often not considered in their evaluation. On the other hand, there are recent data on the relationship of TMs with molecular subtypes and on their prognostic value, the knowledge of which may improve their clinical utility. This consensus article arises from a collaboration between the Spanish Society of Laboratory Medicine (SEQC) and the Spanish Society of Medical Oncology (SEOM). It aims to improve the use and interpretation of circulating TMs in breast cancer. The text summarizes the current knowledge and available evidence on the subject and proposes a series of recommendations mainly focussed on the indication, the frequency of testing and the factors that should be considered for correctly interpreting changes in the levels of TMs.
循环肿瘤标志物（TMs）的测量用于乳腺癌的诊断或监测，有时被认为效用有限。除了对标志物水平的无关变化的过度解释外，在评估时通常不考虑患者、疾病或其他可能改变标志物水平的病理特征。另一方面，最近有关于 TMs 与分子亚型的关系及其预后价值的数据，对这些数据的了解可能会提高其临床实用性。本文由西班牙临床化学和检验医学学会（SEQC）和西班牙肿瘤内科学会（SEOM）合作产生，旨在提高循环 TMs 在乳腺癌中的使用和解释。本文总结了目前关于该主题的知识和可用证据，并提出了一系列建议，主要集中在指示、检测频率以及正确解释 TMs 水平变化时应考虑的因素。
